CXCR4 and ovarian carcinoma: Importantly, studies involving a FVB/NJ immunocompetent mouse model of ovarian carcinoma as well as the use of CXCR4-specific RNAi and AMD3100 have shown that abrogation of CXCR4 robustly decreased intraperitoneal metastasis and almost completely abolished metastasis to the omentum, one of the major sites colonized by ovarian carcinoma [47].